Primary uncommon malignant tumors of the esophagus

an analysis of 30 cases.

Y. K. Lin, L. S. Wang, H. J. Fahn, C. W. Tu, Y. C. Wu, M. H. Huang

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

BACKGROUND. Uncommon malignant tumors of the esophagus are defined as any histological type of malignant esophageal tumors other than the typical squamous cell carcinoma. Their biological characteristics remain obscure because of their rarity. Thus, this is a retrospective review of patients here with uncommon esophageal cancers in an attempt to evaluate their prognostic factors and proper therapeutic modalities. METHODS. Among 1,674 patients with esophageal cancers, only 30 (1.8%) with uncommon esophageal cancers were collected between 1977 and 1992. The clinical parameters for evaluation consisted of age, sex, histological type, location, staging and a variety of therapeutic management techniques and their results. RESULTS. Histologically, there were 10 adenocarcinomas, 7 small cell carcinomas, 6 adenosquamous carcinomas, 3 carcinosarcomas, 1 mucoepidermoid carcinoma, 1 adenoid cystic carcinoma, 1 fibrosarcoma, and 1 basal cell carcinoma. The mean age was 65.8 years, ranging from 46 to 85 years. Upon admission to hospital, the most common clinical symptoms included dysphagia, body weight loss and substernal pain. The tumor staging, according to TNM classification was evaluated as follows: Stage I: 13.3%, Stage II: 46.7%, Stage III: 16.9%, Stage IV: 23.3%. The middle third thoracic esophagus was the most common location of tumor occurrence. Overall one-year, two-year, and five-year survival rates were 39.3%, 21.4%, and 10.7% respectively. These results were as poor as those of squamous cell carcinoma. However, the patients with Stage I and Stage II tumors (mean, 23.8 months) had significantly better survivals than those with Stage III and Stage IV (mean, 3.9 months). Furthermore, if the tumor was resectable, the patients undergoing esophagectomy had much better one-year and two-year survival rates than those without esophagectomy (p <0.01). In addition, patients with small cell carcinoma seemed to have worse treatment outcome than those with other histological types of tumors. CONCLUSIONS. These results suggested that key factors contributing to prognosis included tumor staging as well as respectability. Thus, it is recommended that, with early detection and diagnosis, esophagectomy might be the treatment-of-choice in managing these uncommon esophageal malignancies. Adjuvant therapy including irradiation and chemotherapy may be helpful, particular for small cell carcinoma.

Original languageEnglish
Pages (from-to)463-471
Number of pages9
JournalChinese Medical Journal (Taipei)
Volume55
Issue number6
Publication statusPublished - Jun 1995
Externally publishedYes

Fingerprint

Esophagus
Small Cell Carcinoma
Esophagectomy
Neoplasm Staging
Esophageal Neoplasms
Neoplasms
Squamous Cell Carcinoma
Survival Rate
Adenosquamous Carcinoma
Mucoepidermoid Carcinoma
Carcinosarcoma
Adenoid Cystic Carcinoma
Fibrosarcoma
Basal Cell Carcinoma
Therapeutics
Deglutition Disorders
Weight Loss
Early Diagnosis
Adenocarcinoma
Thorax

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lin, Y. K., Wang, L. S., Fahn, H. J., Tu, C. W., Wu, Y. C., & Huang, M. H. (1995). Primary uncommon malignant tumors of the esophagus: an analysis of 30 cases. Chinese Medical Journal (Taipei), 55(6), 463-471.

Primary uncommon malignant tumors of the esophagus : an analysis of 30 cases. / Lin, Y. K.; Wang, L. S.; Fahn, H. J.; Tu, C. W.; Wu, Y. C.; Huang, M. H.

In: Chinese Medical Journal (Taipei), Vol. 55, No. 6, 06.1995, p. 463-471.

Research output: Contribution to journalArticle

Lin, YK, Wang, LS, Fahn, HJ, Tu, CW, Wu, YC & Huang, MH 1995, 'Primary uncommon malignant tumors of the esophagus: an analysis of 30 cases.', Chinese Medical Journal (Taipei), vol. 55, no. 6, pp. 463-471.
Lin YK, Wang LS, Fahn HJ, Tu CW, Wu YC, Huang MH. Primary uncommon malignant tumors of the esophagus: an analysis of 30 cases. Chinese Medical Journal (Taipei). 1995 Jun;55(6):463-471.
Lin, Y. K. ; Wang, L. S. ; Fahn, H. J. ; Tu, C. W. ; Wu, Y. C. ; Huang, M. H. / Primary uncommon malignant tumors of the esophagus : an analysis of 30 cases. In: Chinese Medical Journal (Taipei). 1995 ; Vol. 55, No. 6. pp. 463-471.
@article{997458c932294afa90a88f855fde0ad1,
title = "Primary uncommon malignant tumors of the esophagus: an analysis of 30 cases.",
abstract = "BACKGROUND. Uncommon malignant tumors of the esophagus are defined as any histological type of malignant esophageal tumors other than the typical squamous cell carcinoma. Their biological characteristics remain obscure because of their rarity. Thus, this is a retrospective review of patients here with uncommon esophageal cancers in an attempt to evaluate their prognostic factors and proper therapeutic modalities. METHODS. Among 1,674 patients with esophageal cancers, only 30 (1.8{\%}) with uncommon esophageal cancers were collected between 1977 and 1992. The clinical parameters for evaluation consisted of age, sex, histological type, location, staging and a variety of therapeutic management techniques and their results. RESULTS. Histologically, there were 10 adenocarcinomas, 7 small cell carcinomas, 6 adenosquamous carcinomas, 3 carcinosarcomas, 1 mucoepidermoid carcinoma, 1 adenoid cystic carcinoma, 1 fibrosarcoma, and 1 basal cell carcinoma. The mean age was 65.8 years, ranging from 46 to 85 years. Upon admission to hospital, the most common clinical symptoms included dysphagia, body weight loss and substernal pain. The tumor staging, according to TNM classification was evaluated as follows: Stage I: 13.3{\%}, Stage II: 46.7{\%}, Stage III: 16.9{\%}, Stage IV: 23.3{\%}. The middle third thoracic esophagus was the most common location of tumor occurrence. Overall one-year, two-year, and five-year survival rates were 39.3{\%}, 21.4{\%}, and 10.7{\%} respectively. These results were as poor as those of squamous cell carcinoma. However, the patients with Stage I and Stage II tumors (mean, 23.8 months) had significantly better survivals than those with Stage III and Stage IV (mean, 3.9 months). Furthermore, if the tumor was resectable, the patients undergoing esophagectomy had much better one-year and two-year survival rates than those without esophagectomy (p <0.01). In addition, patients with small cell carcinoma seemed to have worse treatment outcome than those with other histological types of tumors. CONCLUSIONS. These results suggested that key factors contributing to prognosis included tumor staging as well as respectability. Thus, it is recommended that, with early detection and diagnosis, esophagectomy might be the treatment-of-choice in managing these uncommon esophageal malignancies. Adjuvant therapy including irradiation and chemotherapy may be helpful, particular for small cell carcinoma.",
author = "Lin, {Y. K.} and Wang, {L. S.} and Fahn, {H. J.} and Tu, {C. W.} and Wu, {Y. C.} and Huang, {M. H.}",
year = "1995",
month = "6",
language = "English",
volume = "55",
pages = "463--471",
journal = "Journal of the Chinese Medical Association",
issn = "1726-4901",
publisher = "Elsevier Taiwan LLC",
number = "6",

}

TY - JOUR

T1 - Primary uncommon malignant tumors of the esophagus

T2 - an analysis of 30 cases.

AU - Lin, Y. K.

AU - Wang, L. S.

AU - Fahn, H. J.

AU - Tu, C. W.

AU - Wu, Y. C.

AU - Huang, M. H.

PY - 1995/6

Y1 - 1995/6

N2 - BACKGROUND. Uncommon malignant tumors of the esophagus are defined as any histological type of malignant esophageal tumors other than the typical squamous cell carcinoma. Their biological characteristics remain obscure because of their rarity. Thus, this is a retrospective review of patients here with uncommon esophageal cancers in an attempt to evaluate their prognostic factors and proper therapeutic modalities. METHODS. Among 1,674 patients with esophageal cancers, only 30 (1.8%) with uncommon esophageal cancers were collected between 1977 and 1992. The clinical parameters for evaluation consisted of age, sex, histological type, location, staging and a variety of therapeutic management techniques and their results. RESULTS. Histologically, there were 10 adenocarcinomas, 7 small cell carcinomas, 6 adenosquamous carcinomas, 3 carcinosarcomas, 1 mucoepidermoid carcinoma, 1 adenoid cystic carcinoma, 1 fibrosarcoma, and 1 basal cell carcinoma. The mean age was 65.8 years, ranging from 46 to 85 years. Upon admission to hospital, the most common clinical symptoms included dysphagia, body weight loss and substernal pain. The tumor staging, according to TNM classification was evaluated as follows: Stage I: 13.3%, Stage II: 46.7%, Stage III: 16.9%, Stage IV: 23.3%. The middle third thoracic esophagus was the most common location of tumor occurrence. Overall one-year, two-year, and five-year survival rates were 39.3%, 21.4%, and 10.7% respectively. These results were as poor as those of squamous cell carcinoma. However, the patients with Stage I and Stage II tumors (mean, 23.8 months) had significantly better survivals than those with Stage III and Stage IV (mean, 3.9 months). Furthermore, if the tumor was resectable, the patients undergoing esophagectomy had much better one-year and two-year survival rates than those without esophagectomy (p <0.01). In addition, patients with small cell carcinoma seemed to have worse treatment outcome than those with other histological types of tumors. CONCLUSIONS. These results suggested that key factors contributing to prognosis included tumor staging as well as respectability. Thus, it is recommended that, with early detection and diagnosis, esophagectomy might be the treatment-of-choice in managing these uncommon esophageal malignancies. Adjuvant therapy including irradiation and chemotherapy may be helpful, particular for small cell carcinoma.

AB - BACKGROUND. Uncommon malignant tumors of the esophagus are defined as any histological type of malignant esophageal tumors other than the typical squamous cell carcinoma. Their biological characteristics remain obscure because of their rarity. Thus, this is a retrospective review of patients here with uncommon esophageal cancers in an attempt to evaluate their prognostic factors and proper therapeutic modalities. METHODS. Among 1,674 patients with esophageal cancers, only 30 (1.8%) with uncommon esophageal cancers were collected between 1977 and 1992. The clinical parameters for evaluation consisted of age, sex, histological type, location, staging and a variety of therapeutic management techniques and their results. RESULTS. Histologically, there were 10 adenocarcinomas, 7 small cell carcinomas, 6 adenosquamous carcinomas, 3 carcinosarcomas, 1 mucoepidermoid carcinoma, 1 adenoid cystic carcinoma, 1 fibrosarcoma, and 1 basal cell carcinoma. The mean age was 65.8 years, ranging from 46 to 85 years. Upon admission to hospital, the most common clinical symptoms included dysphagia, body weight loss and substernal pain. The tumor staging, according to TNM classification was evaluated as follows: Stage I: 13.3%, Stage II: 46.7%, Stage III: 16.9%, Stage IV: 23.3%. The middle third thoracic esophagus was the most common location of tumor occurrence. Overall one-year, two-year, and five-year survival rates were 39.3%, 21.4%, and 10.7% respectively. These results were as poor as those of squamous cell carcinoma. However, the patients with Stage I and Stage II tumors (mean, 23.8 months) had significantly better survivals than those with Stage III and Stage IV (mean, 3.9 months). Furthermore, if the tumor was resectable, the patients undergoing esophagectomy had much better one-year and two-year survival rates than those without esophagectomy (p <0.01). In addition, patients with small cell carcinoma seemed to have worse treatment outcome than those with other histological types of tumors. CONCLUSIONS. These results suggested that key factors contributing to prognosis included tumor staging as well as respectability. Thus, it is recommended that, with early detection and diagnosis, esophagectomy might be the treatment-of-choice in managing these uncommon esophageal malignancies. Adjuvant therapy including irradiation and chemotherapy may be helpful, particular for small cell carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0029314643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029314643&partnerID=8YFLogxK

M3 - Article

VL - 55

SP - 463

EP - 471

JO - Journal of the Chinese Medical Association

JF - Journal of the Chinese Medical Association

SN - 1726-4901

IS - 6

ER -